AI is revolutionizing urology, enhancing imaging, pathology, and endoscopy, with potential for AI-guided procedures like cystoscopy and ureteroscopy. Virtual scribes and similar AI tools aim to ...

The AUSCO study assessed the artificial urinary sphincter's impact on incontinence and quality of life in men post-prostate surgery or with other urinary issues. Conducted across 18 sites, the study ...

PSMA-PET imaging enhances precision in radiation therapy for prostate cancer, improving treatment efficacy by accurately targeting cancerous areas. Emory study showed PET-guided radiation ...

The study involved a large international, multi-center cohort of approximately 4,000 patients undergoing inflatable penile prosthesis surgery. No significant differences in intraoperative or ...

Standardized guidelines for chaperone use are crucial to ensure consistency and enhance the patient-physician experience in genitourinary exams. Institutions vary in who can serve as a chaperone, with ...

Patient satisfaction is high due to the adaptive delivery of information and encouragement of feedback. Jenson incorporates common patient concerns into lectures, ensuring comprehensive information ...

Aquablation with the HYDROS System integrates AI, cystoscopic, and ultrasonic imaging for personalized treatment planning in benign prostatic hyperplasia. Understanding transrectal ultrasonography, ...

ONCT-534 trial was terminated due to lack of clinically meaningful improvement and dose-limiting toxicity in high-dose patients. Updated data showed potential in twice-daily dosing, with one patient ...

mCSPC and mHSPC refer to prostate cancer with metastases that remain responsive to hormone therapy, often used interchangeably. Both conditions involve the presence of metastases and sensitivity to ...

The TALAPRO-2 study authors noted that the use of androgen receptor (AR)–targeted therapy in clinical practice has increased considerably in recent years. How might prior use of AR-targeted therapy ...

ALLO-316 demonstrates significant anti-tumor activity in CD70-positive advanced ccRCC, with a 50% overall response rate in high CD70 expression patients. The therapy maintains a manageable safety ...

mCSPC treatment requires personalized approaches, considering disease burden, patient comorbidities, and genetic profiles to optimize outcomes. There is a significant need for more effective ...